Enhancing sensitivity of triple-negative breast cancer to DNA-damaging therapy through chemical inhibition of the m6A methyltransferase METTL3

Bianca Cesaro; Alessia Iaiza; Fabio Piscopo; Marco Tarullo; Eleonora Cesari; Dante Rotili; Antonello Mai; Alberto Diana; Michela Londero; Luca Del Giacco; Riccardo Masetti; Alba Di Leone; Chiara Naro; Silvia Masciarelli; Giulia Fontemaggi; Claudio Sette; Francesco Fazi; Alessandro Fatica

doi:10.1002/cac2.12509

Cancer Communications ›› 2024, Vol. 44 ›› Issue (2) : 282-286. DOI: 10.1002/cac2.12509

LETTER TO THE EDITOR

Enhancing sensitivity of triple-negative breast cancer to DNA-damaging therapy through chemical inhibition of the m6A methyltransferase METTL3

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Bianca Cesaro, Alessia Iaiza, Fabio Piscopo, Marco Tarullo, Eleonora Cesari, Dante Rotili, Antonello Mai, Alberto Diana, Michela Londero, Luca Del Giacco, Riccardo Masetti, Alba Di Leone, Chiara Naro, Silvia Masciarelli, Giulia Fontemaggi, Claudio Sette, Francesco Fazi, Alessandro Fatica. Enhancing sensitivity of triple-negative breast cancer to DNA-damaging therapy through chemical inhibition of the m6A methyltransferase METTL3. Cancer Communications, 2024, 44(2): 282‒286 https://doi.org/10.1002/cac2.12509

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303-322.

[2]	Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597-601.

[3]	Sturgess K, Yankova E, Vijayabaskar MS, Isobe T, Rak J, Kucinski I, et al. Pharmacological inhibition of METTL3 impacts specific haematopoietic lineages. Leukemia. 2023;37(10):2133-2137.

[4]	Petri BJ, Klinge CM. m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer. J Mol Endocrinol. 2022;70(2):e220110.

[5]	Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.

[6]	Xiang Y, Laurent B, Hsu CH, Nachtergaele S, Lu Z, Sheng W, et al. RNA m(6)A methylation regulates the ultraviolet-induced DNA damage response. Nature. 2017;543(7646):573-576.

[7]	Zhang C, Chen L, Peng D, Jiang A, He Y, Zeng Y, et al. METTL3 and N6-methyladenosine promote homologous recombination-mediated repair of DSBs by modulating DNA-RNA hybrid accumulation. Mol Cell. 2020;79(3):425-442.

[8]	Li E, Xia M, Du Y, Long K, Ji F, Pan F, et al. METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis. Elife. 2022;11:e75231.

[9]	Li Y, He X, Lu X, Gong Z, Li Q, Zhang L, et al. METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions. Nat Commun. 2022;13(1):6350.

[10]	Londero M, Gallo A, Cattaneo C, Ghilardi A, Ronzio M, Del Giacco L, et al. NF-YAl drives EMT in Claudin^low tumours. Cell Death Dis. 2023;14(1):65.